Cardiff Metropolitan University
Browse
11198.pdf (409.88 kB)

A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial

Download (409.88 kB)
journal contribution
posted on 2022-12-19, 13:34 authored by Omar Mukhtar, Joseph Cheriyan, John R. Cockcroft, David Collier, James M. Coulson, Indranil Dasgupta, Luca Faconti, Mark Glover, Anthony M. Heagerty, Teck K. Khong, Gregory Y.H. Lip, Adrian P. Mander, Mellone N. Marchong, Una Martin, Barry McDonnell, Carmel M. McEniery, Sandosh Padmanabhan, Manish Saxena, Peter J. Sever, Julian I. Shiel, Ian B. Wilkinson

Background

Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a “black versus white” approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia.


Study design

The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure.


Conclusion

AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.

History

Published in

American Heart Journal

Publisher

Elsevier

Version

  • VoR (Version of Record)

Citation

Mukhtar, O., Cheriyan, J., Cockcroft, J.R., Collier, D., Coulson, J.M., Dasgupta, I., Faconti, L., Glover, M., Heagerty, A.M., Khong, T.K., Lip, G.Y., Mander, A.P., Marchong, M.N., Martin, U., McDonnell, B. et al (2018) 'A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono-or dual therapy) on the basis of ethnicity: The comparIson of Optimal Hypertension Regimens; part of the Ancestry Informative Markers in Hypertension program - AIM-HY INFORM trial', American Heart Journal, 204, pp.102-108.

Print ISSN

0002-8703

Electronic ISSN

1097-6744

Cardiff Met Affiliation

  • Cardiff School of Sport and Health Sciences

Cardiff Met Authors

John Cockcroft Barry McDonnell

Cardiff Met Research Centre/Group

  • Cardiovascular Physiology

Copyright Holder

  • © The Authors

Language

  • en

Usage metrics

    Cardiovascular Health & Ageing - Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC